ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
ADC Therapeutics SA Common Shares (ADCT)
Company Research
Source: GlobeNewswire
Initial data from 15 patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL) show 13 patients achieved a complete response and one patient achieved a partial response with ZYNLONTA® All patients achieving responses maintained them at the time of data cutoff ZYNLONTA was generally well-tolerated and safety was consistent with known profile Data were presented at Lymphoma Research Foundation’s 2024 Marginal Zone Lymphoma Scientific Workshop LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL). The 50-patient single-arm, open-label Phase 2 multicenter study is currently being conducted at the Sylvester Comprehensive Cancer Center at University of Miami and City of Hope, and led by Izidore Los
Show less
Read more
Impact Snapshot
Event Time:
ADCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADCT alerts
High impacting ADC Therapeutics SA Common Shares news events
Weekly update
A roundup of the hottest topics
ADCT
News
- ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQGlobeNewswire
- Antibody Drug Conjugates (ADC) Size, Share & Trends Analysis Report 2024: Global Market to Surpass $24 Billion by 2030, Driven by a Strong Product Pipeline & Rising Incidence and Prevalence Of Cancer [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics SA (NYSE:ADCT) First-Quarter Results: Here's What Analysts Are Forecasting For This Year [Yahoo! Finance]Yahoo! Finance
- ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare ConferenceGlobeNewswire
ADCT
Earnings
- 5/6/24 - Beat
ADCT
Sec Filings
- 5/14/24 - Form 8-K
- 5/10/24 - Form 4
- 5/9/24 - Form 4
- ADCT's page on the SEC website